Views: 63 Author: Unibest Industrial Publish Time: 2024-10-22 Origin: Site
Report generated for the week of 2024-10-21 by Unibest Digital Center. Current analysis scope only include the US FDA.
This week, there are 3 drugs in the patent and exclusivity list. They are:
- BRISTOL-MYERS SQUIBB CO's ABRAXANE, containing active ingredient PACLITAXEL
- VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
- BAUSCH AND LOMB INC's XIPERE, containing active ingredient TRIAMCINOLONE ACETONIDE
From BRISTOL-MYERS SQUIBB CO
Approved in Jan 7, 2005, used as Reference Listed Drug and Reference Standard
There are 15 future patent(s) for this application. The earliest expires on 2025-04-27, and the latest expires on 2034-07-12.
Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
---|---|---|---|
7820788 | U-1290 | TREATMENT OF LUNG CANCER | 2024-10-27 |
7820788 | U-1092 | TREATMENT OF BREAST CANCER | 2024-10-27 |
7820788 | U-1434 | TREATMENT OF PANCREATIC CANCER | 2024-10-27 |
From VERTEX PHARMACEUTICALS INC
Approved in Apr 26, 2023, used as Reference Listed Drug and Reference Standard
There are 2 future exclusivity(ies) for this drug product. The earliest expires on 2026-04-26, and the latest expires on 2030-04-26.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2024-10-21 | NEW CHEMICAL ENTITY |
Approved in Apr 26, 2023, used as Reference Listed Drug
There are 2 future exclusivity(ies) for this drug product. The earliest expires on 2026-04-26, and the latest expires on 2030-04-26.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2024-10-21 | NEW CHEMICAL ENTITY |
From VERTEX PHARMACEUTICALS INC
Approved in Oct 21, 2019, used as Reference Listed Drug and Reference Standard
There are 3 future exclusivity(ies) for this drug product. The earliest expires on 2026-10-21, and the latest expires on 2028-06-08.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2024-10-21 | NEW CHEMICAL ENTITY |
Approved in Jun 8, 2021, used as Reference Listed Drug
There are 3 future exclusivity(ies) for this drug product. The earliest expires on 2026-10-21, and the latest expires on 2028-06-08.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2024-10-21 | NEW CHEMICAL ENTITY |
From BAUSCH AND LOMB INC
Approved in Oct 22, 2021, used as Reference Listed Drug and Reference Standard
There are no future exclusivities for this application.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2024-10-22 | NEW PRODUCT |